Company Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
6.11 USD -7.56% Intraday chart for Altimmune, Inc. -5.34% -45.69%

Business Summary

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Number of employees: 59

Sales per Business

USD in Million2022Weight2023Weight Delta
Treatments for Various Diseases and Disorders, and Vaccines
100.0 %
0 100.0 % 0 100.0 % -726.47%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -726.47%

Managers

Managers TitleAgeSince
Chief Executive Officer 67 18-11-29
Director of Finance/CFO 66 21-12-30
Compliance Officer - 22-01-31
Chief Tech/Sci/R&D Officer 65 12-11-30
Chief Tech/Sci/R&D Officer - 15-02-28
Chief Tech/Sci/R&D Officer 71 19-09-08
Corporate Officer/Principal - 20-08-31
Comptroller/Controller/Auditor - 20-09-30
56 -
Corporate Officer/Principal 52 22-12-31

Members of the board

Members of the board TitleAgeSince
Chairman 76 10-03-31
Director/Board Member 72 04-07-31
Director/Board Member 56 03-08-31
Chief Executive Officer 67 18-11-29
Director/Board Member 86 09-12-31
Director/Board Member 69 18-08-29
Director/Board Member 72 20-05-10
Director/Board Member 71 23-03-22
Director/Board Member 74 12-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,902,191 70,351,925 ( 99.22 %) 0 99.22 %

Shareholders

NameEquities%Valuation
8,649,270 12.20 % 65 M $
BlackRock Advisors LLC
5.450 %
3,864,446 5.450 % 29 M $
Vanguard Fiduciary Trust Co.
4.413 %
3,128,728 4.413 % 23 M $
Tang Capital Management LLC
3.879 %
2,750,000 3.879 % 21 M $
Morgan Stanley Investment Management, Inc.
3.120 %
2,211,948 3.120 % 17 M $
Ameriprise Trust Co.
2.411 %
1,709,304 2.411 % 13 M $
Millennium Management LLC
2.243 %
1,590,150 2.243 % 12 M $
Geode Capital Management LLC
1.744 %
1,236,798 1.744 % 9 M $
Fred Alger Management LLC (13f Subfiler)
1.401 %
993,516 1.401 % 7 M $
Susquehanna Securities LLC
1.292 %
916,254 1.292 % 7 M $

Company contact information

Altimmune, Inc.

910 Clopper Road Suite 201S

20878, Gaithersburg

+240 654 1450

http://www.altimmune.com
address Altimmune, Inc.(ALT)
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Company Altimmune, Inc.